Peptides
Vesugen
Also called Vesugen
Vesugen is marketed for circulation and keeping blood vessels healthy with age. People may hope for better exercise tolerance or protection against vascular disease. The cited cell research gives an early rationale, but does not establish that a course clears plaque, treats high blood pressure or prevents a heart attack or stroke.
Dosage & duration
Named oral capsule product example
Peptid.ru Vesugen instruction
Reported use · unapproved regimen- Dose
- 1–2 capsules per administration
- How often
- 1–2 times daily with meals
- How long
- 10–30 days
Describes that supplier’s product course. Capsule fill weight is not a dose of pure injected KED, and clinical efficacy is not established by the directions.
Sources: 2
Do not replace blood-pressure, cholesterol or vascular medication with a peptide course. No oral-to-injection conversion is established.
Why people consider Vesugen
Staying active and looking after circulation
-
Comfortable activity
People hope for better tolerance of walking and exercise.
-
Vessel health with age
Longer-term interest centers on preserving circulation and reducing vascular disease risk.
Why is Vesugen discussed for circulation?
The promise is maintaining vessel function as people age. That sounds relevant to endurance and long-term health, but “better circulation” can mean several different things. A useful claim should specify function, blood pressure or a clinical outcome.
What do the cell findings mean?
The cited study examined signaling markers in vessel-lining cells under laboratory conditions. It did not show that a supplement clears an artery or prevents a cardiovascular event. The paper’s broad introductory language should not be mistaken for its measured outcome.
Capsule versus injected products
The visible course belongs to a named oral product. Research vials may carry the peptide name but cannot inherit that capsule’s amount, delivery or result. A short course is a product instruction, not proof of lasting vessel rejuvenation.
Keep risk-factor care concrete
Blood pressure, cholesterol, smoking and diabetes require their own assessment and management. A peptide should not be treated as protection that permits those risks to go unaddressed. New chest pain or sudden neurological symptoms need urgent care.
Model details: Vesugen · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 4.08 h is an assumption; no timed parent-peptide plasma data in inspected originals.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 4.08 hours
- Absorption half-life assumed
- 1.02 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Do not substitute activity duration or donor-cell aging endpoints for elimination.
- No route-specific F established.
- [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis].
Legacy 4.08 h is an assumption; no timed parent-peptide plasma data in inspected originals.
vesugen-relative-timing-2026-10 · version 1
Common questions
Does Vesugen remove plaque?
The cited cell experiment does not demonstrate plaque removal in people. A vessel-support claim is not that clinical result.
Can it replace blood-pressure treatment?
No evidence reviewed here establishes an equivalent treatment or safe replacement plan. Prescribed risk-factor care should not be changed based on a peptide label.
Sources Labels, studies and notes behind this guide
Catalog evidence: Other human research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- A support label does not establish plaque removal.
- Cell research
- A vessel-cell marker is not a blood-pressure or event outcome.
- Product directions
- This is not a validated injectable vascular treatment.
- 1. Kozlov et al.: KED vascular-cell experiment
Original abstract inspected: in-vitro endothelial models, expression markers, not clinical event prevention.
- 2. Peptid.ru Vesugen capsule instructions
Supplier’s own instructions inspected:1–2 capsules1–2 times daily with food,10–30-day course. Broad treatment and safety assertions not adopted.
- 3. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis].
Legacy 4.08 h is an assumption; no timed parent-peptide plasma data in inspected originals.
- 4. Gene expression in aging stem-cell cultures, 2020
KED, AED and KE at nanomolar concentrations in cultured human embryo-derived mesenchymal cells.
- 5. Pinealon/Vesugen clinical biomarker report, 2015
Limited clinical report with surrogate biological-age/biochemical observations; not a cardiovascular-outcomes trial.
Keep reading
Related compounds and examples
Related compounds
Cartalax
Cartalax for joint comfort and cartilage questions: reported amounts, realistic recovery expectations and why less pain does not prove cartilage regrowth.
Pinealon
Pinealon for memory and brain-aging questions: capsule versus injection amounts, realistic expectations and what its research actually measures.
Epithalon (Epitalon)
Epithalon for sleep and longevity: reported dose ranges, Epithalamin confusion and why telomere changes do not prove longer life.